ClinicalTrials.gg
Enrolling by invitationNCT07021105ESP QLB TAPUpdated Jun 13, 2025

COMPARISON OF PLAIN BLOCKS FOR POSTOPERATIVE PAIN MANAGEMENT IN GYNECOLOGICAL ABDOMINAL SURGERIES

An interventional study of ESP Plane block and QLB plane block in Surgery With General Anesthesia, Gynecologic Surgical Procedures and Plane Block, sponsored by Cukurova University. Enrolling by invitation at 1 site in Turkey. Open to female participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Cukurova University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as enrolling by invitation.
  • Registered 5 months after the study started (first participant enrolled Dec 2024, registered May 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years to 69 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Pain, Postoperative by Cukurova University — 4 open to participants now, 4 under way, none of them phase 3. Pain, Postoperative · Cukurova University.

Planned enrollment
10th of 33
80 · median 60
Started
2024
with 10 others
No phase
20 of 33
4 open now
Registered
26th of 33
by date

Among the 33 studies in Pain, Postoperative by Cukurova University, this one is the 10th largest by planned enrollment, is one of 11 that started in 2024, is one of 20 with no phase, and was the 26th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

4 of the 33 studies in Pain, Postoperative by Cukurova University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 69 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Pain, Postoperative by Cukurova University, or all of them as a file.
02

Study summary

This study compares the effects of transversus abdominis plane (TAP) block, quadratus lumborum block (QLB), and erector spinae plane block (ESP) on postoperative morphine consumption, pain scores, patient satisfaction, and side effects in patients undergoing gynecological abdominal laparotomy surgeries.

Read the detailed description

Patients will be randomly assigned into four groups using a computer-generated randomization method. According to group allocation, patients will receive the following interventions before extubation under ultrasound (US) guidance except control group:

Group E (n=20): Bilateral erector spinae plane (ESP) block will be performed with 40 ml of 0.25% bupivacaine (20 ml on each side) at the T12 level, approximately 3-4 cm laterally from the midline, in the neurofascial plane between the transverse processes and the erector spinae muscle.

Group Q (n=20): Bilateral quadratus lumborum block (QLB) will be performed with 40 ml of 0.25% bupivacaine (20 ml on each side), placed between the psoas major and quadratus lumborum muscles under US guidance, between the iliac crest and the 12th rib.

Group T (n=20): Bilateral transversus abdominis plane (TAP) block will be performed with 40 ml of 0.25% bupivacaine (20 ml on each side) in the neurofascial plane between the internal oblique and transversus abdominis muscles.

Group C (Control group, n=20): No block will be applied, only the standard intravenous patient-controlled analgesia (PCA) protocol will be used.

The primary aim of this study is to assess the morphine consumption in the postoperative period, while secondary aims include pain score, patient satisfaction, the need for rescue analgesia and side effects

03

Conditions studied

  • Surgery With General Anesthesia
  • Gynecologic Surgical Procedures
  • Plane Block
  • Postoperative Pain Management

Browse trials for

Keywords

  • Gynecologic surgery
  • Transversus abdominis plane block
  • Erector spinae plaen block
  • Quadratus lumborum block
  • morphine consumption
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

aged between 18 and 69 years, with ASA 1-2 score scheduled to undergo major gynecological abdominal surgery

Exclusion criteria

Exclusion Criteria:

3 or above, patients younger than 18 or older than 69 years, patients with bleeding disorders or using anticoagulants, patients with a over 40, patients with known allergies to any drugs used in the study, and patients who could not or did not wish to use Patient-Controlled Analgesia (PCA) device

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Group E

    Group ESP \& QLB, TAP, Control

    Procedure: QLB plane block · Procedure: TAP Block · Other: No intervention

  • Active comparator
    Group Q

    Group QLB \& ESP, TAP, Control

    Procedure: ESP Plane block · Procedure: TAP Block · Other: No intervention

  • Active comparator
    Group T

    Group T \& ESP, QLB, Control

    Procedure: ESP Plane block · Procedure: QLB plane block · Other: No intervention

  • No intervention
    Group C

    Group C \& ESP, QLB, TAP

Interventions

  • ProcedureESP Plane block

    Group E (n=20): Bilateral erector spinae plane (ESP) block will be performed with 40 ml of 0.25% bupivacaine (20 ml on each side) at the T12 level, approximately 3-4 cm laterally from the midline, in the neurofascial plane between the transverse processes and the erector spinae muscle.

  • ProcedureQLB plane block

    Group Q (n=20): Bilateral quadratus lumborum block (QLB) will be performed with 40 ml of 0.25% bupivacaine (20 ml on each side), placed between the psoas major and quadratus lumborum muscles under US guidance, between the iliac crest and the 12th rib.

  • ProcedureTAP Block

    Group T (n=20): Bilateral transversus abdominis plane (TAP) block will be performed with 40 ml of 0.25% bupivacaine (20 ml on each side) in the neurofascial plane between the internal oblique and transversus abdominis muscles.

  • OtherNo intervention

    Group C (Control group, n=20): No block will be applied, only the standard intravenous patient-controlled analgesia (PCA) protocol will be used.

06

What researchers measure

Primary outcomes

  1. morphine consumption in the postoperative period

    Thus the primary aim of this study was to assess the morphine consumption in the postoperative period

    Time frame: For postoperative 24 hours

Secondary outcomes

  1. pain score (VAS=0-10), patient satisfaction (0-10), the need for rescue analgesia (mg) and side effects

    Secondary outcomes included pain score (VAS=0-10), patient satisfaction (0-10), the need for rescue analgesia (mg) and side effects

    Time frame: For postoperative 24 hours

07

Study locations

1 site
08

References and documents

Related links

Individual participant data

Plan to share: Undecided — Considering but not decided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Aug 2025, 8 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 8 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
Jun 13, 2025
StartActual
Dec 6, 2024
Primary completionEst.
Aug 11, 2025
CompletionEst.
Sep 10, 2025
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07021105
Responsible party
Hakki Unlugenc (Prof Dr, Cukurova University) — Principal investigator
First posted
Jun 13, 2025
Start date
Dec 6, 2024
Primary completion
Aug 11, 2025 (estimated)
Completion
Sep 10, 2025 (estimated)
Last update
Jun 13, 2025

Study contacts

Hakkı Ünlügenç, Professör
study director · Cukurova University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion